Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Genotype 1 hepatitis C infection (confirmed at screening)~* Patient has not received any prior treatment for hepatitis C~* Patient must have had a liver biopsy within 3 years before screening (or between the screening and baseline visit) showing chronic hepatitis C infection~* Must agree to use 2 forms of effective contraception throughout study (both males and females)~Exclusion Criteria:~* Infection with HIV or non genotype 1 hepatitis C~* Liver disease not related to hepatitic C infection~* Hepatic decompensation~* Significant laboratory abnormalities or other active diseases~* Pregnant or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMC435 (Type: EXPERIMENTAL): TMC435 150 mg capsule once daily for 12 weeks in addition to peginterferon alpha-2a (PegIFN alpha-2a) and ribavirin (RBV) for 24 or 48 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 150 mg capsule once daily for 12 weeks in addition to PegIFNα-2a and RBV for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).